Ozempic is not approved for weight loss. Every indication on its label is for adults with type 2 diabetes. Weight loss appears in its trials only as a secondary measurement — and the label's own tables put it at 3.4% to 6.5% of body weight over 30 to 56 weeks. The same molecule is approved for weight management under a different name, Wegovy, at higher doses, where its trials measured about twice to three times as much. This page sets out both records from the documents, and what prescribing Ozempic "off-label" means in practice.
Sources were read on 6 October 2026: the Ozempic prescribing information (Novo Nordisk, DailyMed, effective 1 June 2026), the STEP trial publications, and FDA's guidance on off-label use. This page reports the trials; it does not suggest a drug or a dose for anyone.
What the Ozempic label approves
Section 1 of the label lists three uses, each "in adults with type 2 diabetes mellitus":
| Indication | Since | Trial behind it |
|---|---|---|
| Glycaemic control, with diet and exercise | December 2017 | SUSTAIN programme |
| Reducing major cardiovascular events (with established cardiovascular disease) | January 2020 | SUSTAIN 6 |
| Reducing kidney decline, kidney failure and cardiovascular death (with chronic kidney disease) | January 2025 | FLOW |
The dates and trials are set out on what Ozempic is. Weight appears nowhere in this list. The label does say, in its pharmacology section, that semaglutide "reduces body weight" — a description of what the drug does, not an approved purpose.
What Ozempic's own trials measured on weight
Every glycaemic-control trial in section 14 reports mean body-weight change as a secondary result. The label prints the starting weight and the change in kilograms; the percentages below are glp1ledger's arithmetic from those two figures, which the label does not print itself.
| Trial (label section 14.1) | Weeks | Ozempic 0.5 mg | Ozempic 1 mg | Comparator |
|---|---|---|---|---|
| Monotherapy vs placebo (NCT02054897) | 30 | -3.8 kg (-4.2%) | -4.7 kg (-4.9%) | placebo -1.2 kg (-1.3%) |
| vs sitagliptin (NCT01930188) | 56 | -4.2 kg (-4.7%) | -5.5 kg (-6.2%) | sitagliptin -1.7 kg (-1.9%) |
| vs exenatide ER (NCT01885208) | 56 | — | -4.8 kg (-5.0%) | exenatide -2.0 kg (-2.1%) |
| vs insulin glargine (NCT02128932) | 30 | -3.2 kg (-3.4%) | -4.7 kg (-5.0%) | glargine +0.9 kg (+1.0%) |
| Added to basal insulin (NCT02305381) | 30 | -3.5 kg (-3.8%) | -6.0 kg (-6.5%) | placebo -1.2 kg (-1.3%) |
| 2 mg vs 1 mg (NCT03989232) | 40 | — | -5.6 kg (-5.7%) | Ozempic 2 mg -6.4 kg (-6.4%) |
Means; missing data were imputed by the method the label states ("based on retrieved dropouts"), so people who stopped treatment are counted in their arm. Mean starting weights were 89 to 100 kg.
Three things follow from the label's own numbers. The range at diabetes doses is narrow: 3.4% to 6.5% across six trials and two to three doses. The top dose added little: the label states that the weight difference between 2 mg and 1 mg "was not statistically significant". And the comparators matter: against insulin glargine the gap was 5.6 kg, because glargine arms gained weight; against placebo it was 2.6 to 4.7 kg.
What the weight-management trials of the same molecule measured
The STEP programme tested semaglutide 2.4 mg — the Wegovy dose, above any Ozempic strength — specifically for weight. Two of its results matter here, and they come from different populations and trial designs, so they are set side by side for scale, never as a head-to-head with the table above.
| Trial | Population | Weeks | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|---|
| STEP 1 (NEJM 2021) | Adults with obesity or overweight, without diabetes | 68 | -14.9% (-15.3 kg) | -2.4% |
| STEP 2 (Lancet 2021) | Adults with overweight or obesity and type 2 diabetes | 68 | -9.6% | -3.4% |
STEP 2 is the one that explains a pattern patients notice: people with type 2 diabetes lose less on the same molecule, even at the higher dose. The diabetes trials behind Ozempic's label, run at lower doses and for shorter periods, sit below both. The full trial-by-trial record for the weight-management product is on the semaglutide review.
Why a second product exists
Novo Nordisk did not add a weight indication to Ozempic. It filed a separate application, and FDA approved Wegovy on 4 June 2021 for chronic weight management, with doses escalating to 2.4 mg and, since 2026, a 7.2 mg strength. The two products contain the same molecule but differ in indication, pen strengths, price and how insurers treat them; the side-by-side is on Wegovy vs Ozempic. The practical effect of the split is that a diagnosis decides which product a plan will consider: a diabetes diagnosis for Ozempic, a weight-management prescription for Wegovy.
What "off-label" means in practice
FDA's guidance for patients states that once a drug is approved, health care providers "generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient". So an Ozempic prescription written for weight is legal. Three things change because of it:
- Coverage. Insurers usually tie Ozempic coverage to a type 2 diabetes diagnosis, and many plans exclude weight-management drugs entirely; how the rules are applied, and what a prior authorization asks for, are on GLP-1 prior authorization and GLP-1 insurance coverage.
- The manufacturer's card. Novo's $25 Ozempic offer requires the prescription to be for "an FDA-approved indication within Ozempic's labeling" — the terms are on the Ozempic savings card.
- The evidence. The label's safety and efficacy data come from people with type 2 diabetes. There is no Ozempic-labelled trial in people without diabetes; the evidence for that population is the STEP programme at a different dose and product.
What happens on stopping
The STEP 1 extension followed 327 participants for a year after treatment ended at week 68. Those who had taken semaglutide 2.4 mg had lost a mean 17.3% by week 68 and regained 11.6 percentage points by week 120 — about two-thirds — leaving a net loss of 5.6%. The authors also report that the cardiometabolic improvements moved back toward baseline. No equivalent withdrawal study appears in the Ozempic label. What is known about stopping, tapering and regain is on stopping a GLP-1.
What is not established
- No trial has measured Ozempic in people without diabetes at its labelled doses. The weight figures for that population come from 2.4 mg trials.
- No body-composition data are in the Ozempic label: no waist, fat-mass or lean-mass measurement. Claims about where the weight comes from at Ozempic doses rest on other trials.
- The 2 mg strength was not shown to add weight loss over 1 mg in the one trial that compared them.
Sources
Novo Nordisk, OZEMPIC (semaglutide) injection prescribing information, DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79 (SPL effective 2026-06-01), sections 1, 12.2 and 14.1, read 6 October 2026 · Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity", N Engl J Med 2021;384:989-1002, doi:10.1056/NEJMoa2032183 · Davies M et al., "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)", Lancet 2021, doi:10.1016/S0140-6736(21)00213-0 · Wilding JPH et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension", Diabetes Obes Metab 2022, doi:10.1111/dom.14725 · U.S. FDA, Understanding Unapproved Use of Approved Drugs "Off Label", read 6 October 2026.